Hem › Burkitts lymfom › Maryland
Kliniska studier för Burkitts lymfom i Maryland
11 studier för Burkitts lymfom söker deltagare vid platser i Maryland.
Städer i Maryland
Officiell studietext (engelska)
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Sinai Hospital of Baltimore, Baltimore
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
- Walter Reed National Military Medical Center, Bethesda
RekryterarFas 2
366 Days – 46 Years · Alla kön · Uppdaterad 2 okt. 2026 · NCT06124157Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
- University of Maryland/Greenebaum Cancer Center, Baltimore
RekryterarFas 3
Ålder 18 till 39 · Alla kön · Uppdaterad 2 okt. 2026 · NCT03150693CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies
- National Institutes of Health Clinical Center, Bethesda
RekryterarFas 1/2
Ålder 3 till 39 · Alla kön · Uppdaterad 30 sep. 2026 · NCT05442515Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
- National Institutes of Health Clinical Center, Bethesda
RekryterarFas 1/2
Ålder 18 till 120 · Alla kön · Uppdaterad 28 sep. 2026 · NCT03223610Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Sinai Hospital of Baltimore, Baltimore
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
RekryterarFas 2
365 Days · Alla kön · Uppdaterad 25 sep. 2026 · NCT06317662Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- Johns Hopkins Asthma & Allergy Center, Baltimore
- American Oncology Partners, PA dba The Center for Cancer and Blood Disorders, Bethesda
RekryterarFas 3
Ålder 18 och äldre · Alla kön · Uppdaterad 21 sep. 2026 · NCT07648264Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
- University of Maryland, Baltimore
RekryterarFas 1
Ålder 18 och äldre · Alla kön · Uppdaterad 8 sep. 2026 · NCT03666000A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Sinai Hospital of Baltimore, Baltimore
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
RekryterarFas 2
Ålder 1 till 30 · Alla kön · Uppdaterad 1 sep. 2026 · NCT04546399Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
- National Institutes of Health Clinical Center, Bethesda
RekryterarFas 1
Ålder 18 till 120 · Alla kön · Uppdaterad 25 aug. 2026 · NCT05389423Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- University of Maryland/Greenebaum Cancer Center, Baltimore
- Sinai Hospital of Baltimore, Baltimore
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
- och 1 fler
RekryterarFas 3
365 Days – 25 Years · Alla kön · Uppdaterad 25 aug. 2026 · NCT03959085Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
- University of Maryland, Baltimore
RekryterarFas 1
Ålder 18 och äldre · Alla kön · Uppdaterad 5 nov. 2025 · NCT04260022Från ClinicalTrials.gov, data hämtad 5 okt. 2026. Varje studie har egna kvalifikationskrav; studieteamet avgör vem som kan delta.